Application of gene detection in individualized treatment of lipid-lowering drugs
- VernacularTitle:基因检测在降脂药物个体化治疗中的应用
- Author:
Yangmei ZHU
1
;
Jiangang CAO
2
;
Yusheng ZHOU
2
Author Information
1. Institute of Pharmaceutical Pharmacology，University of South China，Hunan Hengyang 421000，China
2. Institute of Clinical Pharmacy，the Affiliated Nanhua Hospital，University of South China，Hunan Hengyang 421000，China
- Publication Type:Journal Article
- Keywords:
gene detection;
lipid-lowering drugs;
individualized treatment;
gene polymorphism
- From:
China Pharmacy
2023;34(9):1147-1152
- CountryChina
- Language:Chinese
-
Abstract:
The main clinical manifestation of dyslipidemia is hyperlipidemia， which is an important risk factor leading to the occurrence of cardiovascular and cerebrovascular diseases such as atherosclerosis， coronary heart disease and stroke. In clinical practice， lipid-lowering drugs are mainly used for treatment， but there are issues such as individual differences and genetic effects. Therefore， it is necessary to perform gene detection on patients， so as to guide individualized application of lipid-lowering drugs. This review mainly previews the definition of gene detection and the individualized treatment of lipid-lowering drugs， and introduces the application of gene detection in the individualized treatment of lipid-lowering drugs （statins， fibrates， nicotinic acid and ezetimibe）. Among them， the gene polymorphisms of APOE， SLCO1B1 and CYP450 family play a key role in the efficacy and safety of statins； the gene polymorphisms of APOA/B/C family have a significant impact on the efficacy of fenofibrate； the gene polymorphisms of HCAR2 and DGAT2 have an important impact on the efficacy of niacin； the gene polymorphisms of NPC1L1 have a significant impact on the efficacy of ezetimibe. It is suggested to conduct genotype detection for patients with dyslipidemia to select appropriate treatment strategies， so as to provide individualized medication guidance.
